Skip to main content
Log in

Ixazomib: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ixazomib (Ninlaro®) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncology). Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome. In November 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is under regulatory review for this indication in the EU. Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis. Ixazomib is also under phase I–II development for the treatment of several other haematological and non-haematological malignancies, graft-versus-host disease and lupus nephritis. This article summarizes the milestones in the development of ixazomib leading to this first approval for multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moreau P, Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book. 2015;35:e504–11.

    Article  Google Scholar 

  2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Multiple myeloma (version 2.2016). 2015. http://www.nccn.org. Accessed 16 Dec 2015.

  3. Kumar S. Implications of oral proteasome inhibition: impact on patients [abstract no. PS-029]. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3):e14–5.

  4. Millennium Pharmaceuticals. Velcade® (bortezomib): prescribing information. 2015. http://www.velcade.com/. Accessed 16 Dec 2015.

  5. Onyx Pharmaceuticals. Kyprolis® (carfilzomib): prescribing information. 2015. http://www.kyprolis.com/. Accessed 16 Dec 2015.

  6. Moreau P. Oral therapy for multiple myeloma: ixazomib arriving soon. Blood. 2014;124(7):986–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. US FDA. Ninlaro® (ixazomib) capsules: US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf. Accessed 16 Dec 2015.

  8. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–80.

    Article  CAS  PubMed  Google Scholar 

  9. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 study (NCT01564537) [abstract no. 727]. In: 57th ASH Annual Meeting and Exposition. 2015.

  10. US FDA. Ninlaro® (ixazomib) capsules: NDA approval. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/208462Orig1s000ltr.pdf. Accessed 16 Dec 2015.

  11. European Medicines Agency. Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures. 2015. http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500190953. Accessed 16 Dec 2015.

  12. Takeda Pharmaceutical Company Ltd. Takeda announces European Medicines Agency acceptance of ixazomib’s marketing authorization application for patients with relapsed/refractory multiple myeloma [media release]. 2015. http://www.takeda.com/news/2015/20150821_7104.html. Accessed 16 Dec 2015.

  13. Takeda Pharmaceutical Company Ltd. Takeda’s investigational, oral proteasome inhibitor ixazomib granted breakthrough therapy designation by U.S. FDA for relapsed or refractory systemic light-chain amyloidosis [media release]. 2015. http://www.takeda.com/news/2014/20141202_6830.html. Accessed 16 Dec 2015.

  14. ClinicalTrials.org. Ixazomib clinical trials. 2015. http://clinicaltrials.gov/ct2/results?term=ixazomib&Search=Search. Accessed 16 Dec 2015.

  15. Takeda Pharmaceutical Company Ltd. Takeda completes acquisition of Millennium [media release]. 2008. http://www.takeda.com/news/2008/20080515_3619.html. Accessed 16 Dec 2015.

  16. Takeda Pharmaceutical Company Ltd. Takeda announces formalization of Takeda Oncology to enhance discovery, development and global commercialization of breakthrough cancer medicines [media release]. 2014. http://www.takeda.com/news/2014/20141208_6832.html. Accessed 16 Dec 2015.

  17. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011;17(23):7313–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Dashnamoorthy R, Beheshti A, Abermil N, et al. Single agent activity and synergistic drug combinations of ixazomib in preclinical models of T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) [abstract no. 278-P]. In: International Conference on Malignant Lymphoma. 2015.

  20. Evens A, Dashnamoorthy R, Beheshti A, et al. Myc and Chk1 dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models with anti-proteasomal therapy [abstract no. 278]. Hematol Oncol. 2015;33:239.

    Article  Google Scholar 

  21. Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20(6):1542–54.

    Article  CAS  PubMed  Google Scholar 

  22. Gupta N, Noe D, Liu G, et al. Clinical pharmacokinetics (PK) of intravenous (IV) and oral (PO) MLN9708, an investigational proteasome inhibitor: pooled analysis from monotherapy and combination studies across various indications [abstract no. PI-51]. Clin Pharmacol Ther. 2013;93(Suppl 1):S32.

    Google Scholar 

  23. Gupta N, Zhao Y, Hui AM, et al. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2015;79(5):789–800.

    Article  CAS  PubMed  Google Scholar 

  24. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Gupta N, Hanley MJ, Venkatakrishnan K, et al. A phase 1 study of the effect of a high-fat meal on the pharmacokinetics of ixazomib citrate (MLN9708), an investigational oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma [abstract no. P989]. Haematologica. 2014;99(Suppl 1):376.

    Google Scholar 

  26. Gupta N, Hanley MJ, Harvey RD, et al. Phase 1/1b pharmacokinetic (PK) and safety study of the investigational oral proteasome inhibitor (PI) ixazomib in relapsed/refractory multiple myeloma (RRMM) patients (Pts) with severe renal impairment or end-stage renal disease (ESRD) requiring hemodialysis [abstract no. 4227]. In: 57th ASH Annual Meeting and Exposition. 2015.

  27. Gupta N, Hanley MJ, Venkatakrishnan K, et al. A phase 1 study to assess pharmacokinetics (PK) and safety of ixazomib, an oral proteasome inhibitor, in patients with moderate or severe hepatic impairment [abstract no. 3032]. In: 57th ASH Annual Meeting and Exposition. 2015.

  28. Kumar S, Niesvizky R, Berdeja JG, et al. Safety and pharmacokinetics of weekly MLN9708, an investigational oral proteasome inhibitor, alone and in combination [abstract no. P-230]. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 1):S154.

  29. Lonial S, Colson K, Harvey RD, et al. Safety profile of oral ixazomib: experience from 761 patients (pts) across 14 phase 1 or phase 1/2 clinical studies [abstract no. BP-056]. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3):e78–9.

  30. Gupta N, Huh Y, Hutmacher MM, et al. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemother Pharmacol. 2015;76(3):507–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this medical review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. M. Shirley is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matt Shirley.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirley, M. Ixazomib: First Global Approval. Drugs 76, 405–411 (2016). https://doi.org/10.1007/s40265-016-0548-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0548-5

Keywords

Navigation